Alaunos Therapeutics/ US98973P3091 /
2024-07-24 9:55:48 PM | Chg. +0.31 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
4.06USD | +8.27% | 494 Turnover: 1,996.09 |
-Bid Size: - | -Ask Size: - | 4.23 | 3.99 |
GlobeNewswire
06-10
BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer...
GlobeNewswire
01-29
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
GlobeNewswire
2023-11-14
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Conti...
GlobeNewswire
2022-03-16
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022
GlobeNewswire
2022-03-08
Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference
GlobeNewswire
2022-01-26
Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics